Top

BMC Cancer

Published in:

Open Access 01-12-2010 | Research article

Synergistic effect of stromelysin-1 (matrix metalloproteinase-3) promoter (-1171 5A->6A) polymorphism in oral submucous fibrosis and head and neck lesions

Authors: Ajay K Chaudhary, Mamta Singh, Alok C Bharti, Mangal Singh, Shirish Shukla, Atul K Singh, Ravi Mehrotra

Published in: BMC Cancer | Issue 1/2010

Abstract

Background

Matrix metalloproteinases (MMPs) are enzymes that degrade all the components of extra cellular matrix and collagen. Various types of MMPs are known to be expressed and activated in patients with oral submucous fibrosis (OSMF) as well as head and neck squamous cell carcinoma (HNSCC). The purpose of this study was to asses the association of the single nucleotide polymorphism (SNP) adenosine insertion/deletion polymorphism (-1171 5A->6A) in the MMP-3 promoter region in these lesions.

Methods

MMP-3 SNP was genotyped by polymerase chain reaction-restriction fragment polymorphism (PCR-RFLP) analysis in a case control study consisting of 362 participants; 101 cases of OSMF, 135 of HNSCC and 126 controls, compared for age, sex and habits. ROC distribution was plotted to assess the contributions of genetic variation in MMP-3 genotypes with relation to age.

Results

Analysis of MMP 3 (-1171 5A->6A) polymorphism revealed the frequency of 5A allele in OSMF, HNSCC and controls to be 0.15, 0.13 and 0.07, respectively. A significant difference was found in 5A genotype frequency between OSMF (5A genotype frequency = 0.15, p = 0.01, OR = 2.26, 95% CI = 1.22-4.20) and in controls (5A genotype frequency 0.07) as well as HNSCC (5A genotype frequency 0.13, p = 0.03,95%CI = 1.06-3.51) and controls (5A genotype frequency = 0.07) In this study, 5A genotype had greater than two fold risk for developing OSMF (OR = 2.26) and nearly the same in case of HNSCC (OR = 1.94) as compared to controls. In patients with OSMF as well as HNSCC, the ROC analysis between the MMP-3 genotype and age, 6A/6A allele was found to be significant in patients both over and under 45 years of age; while the 5A/5A carrier alleles showed an association only in patients less than 45 years of age.

Conclusions

This study concluded that the expression of MMP-3 genotype associated with the 5A alleles, it may have an important role in the susceptibility of the patients to develop OSMF and HNSCC.

Available only for authorised users

Vihinen P, Kähäri VM: Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer. 2002, 99 (2): 157-66. 10.1002/ijc.10329.CrossRefPubMed

Matrisian LM: Cancer biology. Extracellular proteinases in malignancy. Curr Biol. 1999, 9: 776-778. 10.1016/S0960-9822(00)80011-1.CrossRef

Impola U, Uitto VJ, Hietanen J, Hakkinen L, Zhang L, Larjava H, Isaka K, Saarialho-Kere U: Differential expression of matrilysin-1 (MMP-7), 92 kD gelatinase (MMP-9), and metalloelastase (MMP-12) in oral verrucous and squamous cell cancer. J Pathol. 2004, 202 (1): 14-22. 10.1002/path.1479.CrossRefPubMed

Brinckerhoff CE, Rutter JL, Benbow U: Interstitial collagenases as markers of tumor progression. Clin Cancer Res. 2000, 6 (12): 4823-4830.PubMed

Johanssona N, Ahonenb M, Kähäri VM: Matrix metalloproteinases in tumor invasion. Cell Mol Life Sci. 2000, 57: 5-15. 10.1007/s000180050495.CrossRef

Sage EH, Reed M, Funk SE, Truong T, Steadele M, Puolakkainen P, Maurice DH, Bassuk JA: Cleavage of the matricellular protein SPARC by matrix metalloproteinase 3 produces polypeptides that influence angiogenesis. J Biol Chem. 2003, 278: 37849-37857. 10.1074/jbc.M302946200.CrossRefPubMed

Chaudhary AK, Singh M, Bharti AC, Asotra K, Sundaram S, Mehrotra R: Genetic polymorphisms of matrix metalloproteinases and their inhibitors in potentially malignant and malignant lesions of the head and neck. J Biomed Sci. 2010, 17: 10-10.1186/1423-0127-17-10.CrossRefPubMedPubMedCentral

Kahari VM, Saarialho-Kere U: Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med. 1999, 31: 34-45. 10.3109/07853899909019260.CrossRefPubMed

Zinzindohouém F, Blons H, Hans S, Loriot MA, Houllier AM, Brasnu D, Laccourreye O, Tregouet DA, Stucker I, Laurent-Puig P: Single nucleotide polymorphisms in MMP1 and MMP3 gene promoters as risk factor in head and neck squamous cell carcinoma. Anticancer Res. 2004, 24 (3b): 2021-6.

10.

Hashimoto T, Uchida K, Okayama N, Imate Y, Suehiro Y, Hamanaka Y, Ueyama Y, Shinozaki F, Yamashita H, Hinoda Y: Association of matrix metalloproteinase (MMP)-1 promoter polymorphism with head and neck squamous cell carcinoma. Cancer Lett. 2004, 211 (1): 19-24. 10.1016/j.canlet.2004.01.032.CrossRefPubMed

11.

Fang S, Jin X, Wang R, Li Y, Guo W, Wang N, Wang Y, Wen D, Wei L, Zhang J: Polymorphisms in the MMP1 and MMP3 promoter and non-small cell lung carcinoma in North China. Carcinogenesis. 2005, 26: 481-486. 10.1093/carcin/bgh327.CrossRefPubMed

12.

Ghilardi G, Biondi ML, Caputo M, Leviti S, DeMonti M, Guagnellini E, Scorza R: A single nucleotide polymorphism in the matrix metalloproteinase-3 promoter enhances breast cancer susceptibility. Clin Cancer Res. 2002, 8 (12): 3820-3823.PubMed

13.

Ashworth JL, Murphy G, Rock MJ: Fibrillin degradation by matrix metalo protienase: Implication for connective tissue remodelling. Biochem J. 1999, 340 (Pt 1): 171-81. 10.1042/0264-6021:3400171.CrossRefPubMedPubMedCentral

14.

Ye S, Eriksson P, Hamsten A, Kurkinen M, Humphries SE, Henney AM: Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem. 1996, 271 (22): 13055-13060. 10.1074/jbc.271.22.13244.CrossRefPubMed

15.

Ye S, Watts GF, Mandalia S, Humphries SE, Henney AM: Preliminary report; genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J. 1995, 73: 209-15. 10.1136/hrt.73.3.209.CrossRefPubMedPubMedCentral

16.

Su L, Zhou W, Asomaning K, Lin X, Wain JC, Lynch TJ, Liu G, Christiani DC: Genotypes and haplotypes of matrix metalloproteinase 1, 3 and 12 genes and the risk of lung cancer. Carcinogenesis. 2006, 27: 1024-1029. 10.1093/carcin/bgi283.CrossRefPubMed

17.

Gnasso A, Motti C, Irace C, Carallo C, Liberatoscioli L, Bernardini S, Massoud R, Mattioli PL, Federici G: Genetic variation in human stromelysin gene promoter and common carotid geometry in healthy male subjects. Arterioscler Thromb Vasc Biol. 2000, 20: 1600-1605.CrossRefPubMed

18.

Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2003, 100: 57-70. 10.1016/S0092-8674(00)81683-9.CrossRef

19.

Nagata M, Fujita H, Ida H, Hoshina H, Inoue T, Seki Y, Ohnishi M, Ohyama T, Shingaki S, Kaji M: Identification of potential biomarkers of lymph node metastasis in oral squamous cell carcinoma by cDNA microarray analysis. Int J Cancer. 2003, 106 (5): 683-689. 10.1002/ijc.11283.CrossRefPubMed

20.

Lin SC, Lo SS, Liu CJ, Chung MY, Huang JW, Chang KW: Functional genotype in matrix metalloproteinases-2 promoter is a risk factor for oral carcinogenesis. J Oral Pathol Med. 2004, 33: 405-9. 10.1111/j.1600-0714.2004.00231.x.CrossRefPubMed

21.

Lin SC, Chung MY, Huang JW, Shieh TM, Liu CJ, Chang KW: Correlation between functional genotypes in the matrix metalloproteinases-1 promoter and risk of oral squamous cell carcinomas. J Oral Pathol Med. 2004, 33: 323-6.CrossRefPubMed

22.

Tu HF, Liu CJ, Chang CS, Lui MT, Kao SY, Chang CP, Liu TY: The functional -1171 (5A/6A) polymorphisms of matrix metalloproteinase 3 gene as a risk factor for oral submucous fibrosis among male areca users. Oral Pathol Med. 2006, 3 (5): 99-103. 10.1111/j.1600-0714.2006.00370.x.CrossRef

23.

Pandya S, Chaudhary AK, Sngh M, Mehrotra R: Correlation of histopathological diagnosis with habits and clinical findings in oral submucous fibrosis. Head & neck Oncology. 2009, 1 (1): 11-10.1186/1758-3284-1-10.CrossRef

24.

Chiu CJ, Chiang CP, Chang ML: Association between genetic polymorphism of tumour necrosis factor-alpha and risk of oral submucous fibrosis, a pre cancerous condition of oral cancer. J Dent Res. 2001, 80 (12): 2055-2059. 10.1177/00220345010800120601.CrossRefPubMed

25.

Shin YN, Lin CJ, Chang KW, Lee YJ, Liu HF: Association of CTLA-4 gene polymorphism with oral submucous fibrosis in Taiwan. J Oral Pathol Med. 2004, 33: 200-3. 10.1111/j.0904-2512.2004.00081.x.CrossRefPubMed

26.

Vairaktaris E, Yapijakis C, Vasiliou S, Derka S, Nkenke E, Serefoglou Z, Vorris E: Association of -1171 promoter polymorphism of matrix metalloproteinase-3 with increase risk for oral cancer. Anticancer Res. 2007, 27 (6B): 4095-100.PubMed

27.

28.

Zhang J, Jin X, Fang S, Li Y, Wang R, Guo W, Wang N, Wang Y, Wen D, Wei L, Kuang G, Dong Z: The functional SNP in the matrix metalloproteinase-3 promoter modifies susceptibility and lymphatic metastasis in esophageal squamous cell carcinoma but not in gastric cardiac adenocarcinoma. Carcinogenesis. 2004, 25: 2519-2524. 10.1093/carcin/bgh269.CrossRefPubMed

29.

Blons H, Gad S, Zinzindohoué F, Manière I, Beauregard J, Tregouet D, Brasnu D, Beaune P, Laccourreye O, Laurent-Puig P: Matrix metalloproteinase 3 polymorphism: a predictive factor of response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma. Clin Cancer Res. 2004, 10 (8): 2594-9. 10.1158/1078-0432.CCR-1116-03.CrossRefPubMed

30.

Smolarz B, Szyłło K, Romanowicz-Makowska H, Niewiadomski M, Kozłowska E, Kulig A: PCR analysis of matrix metalloproteinase 3 (MMP-3) gene promoter polymorphism in ovarian cancer. Pol J Pathol. 2003, 54 (4): 233-8.PubMed

31.

Yoon S, Tromb G, Vongpunsawad S, Ronkainen A, Juvonen T, Kuivaniemi H: Genetic analysis of MMP3 and MMP9 and PAI-1 in Finnish patients with abdominal aortic or intracranial aneurysms. Biochem Biophys Res Communic. 1999, 265: 563-568. 10.1006/bbrc.1999.1721.CrossRef

32.

Hinoda Y, Okayama N, Takano N, Fujimura K, Suehiro Y, Hamanaka Y, Hazama S, Kitamura Y, Kamatani N, Oka M: Association of functional polymorphisms of matrix metalloproteinase-1 (MMP-1) and MMP-3 genes with colorectal cancer. Int J Cancer. 2002, 102: 526-529. 10.1002/ijc.10750.CrossRefPubMed

33.

Nishijima C, Hayakawa I, Matsushita T, Komura K, Hasegawa M, Takehara K, Sato S: Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis. Clin Exp Immunol. 2004, 138 (2): 357-63. 10.1111/j.1365-2249.2004.02615.x.CrossRefPubMedPubMedCentral

34.

Murawaki Y, Ikuta Y, Idobe Y, Kawasaki H: Serum matrixmetalloproteinase-1 in patients with chronic viral hepatitis. J Gastroenterol Hepatol. 1999, 14 (2): 138-45. 10.1046/j.1440-1746.1999.01821.x.CrossRefPubMed

35.

Visse R, Nagase H: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function and biochemistry. Circ Res. 2003, 92: 827-839. 10.1161/01.RES.0000070112.80711.3D.CrossRefPubMed

36.

Strup-Perrot C, Mathé D, Linard C, Violot D, Milliat F, François A, Bourhis J, Vozenin-Brotons MC: Global gene expression profiles reveal an increase in mRNA levels of collagens, MMPs, and TIMPs in late radiation enteritis. Am J Physiol Gastrointest Liver Physiol. 2004, 287 (4): G875-85. 10.1152/ajpgi.00088.2004.CrossRefPubMed

37.

Chang YC, Yang SF, Tai KW, Chou MY, Hsieh S: Increased tissue inhibitor of metalloproteinase-1 expression and inhibition of gelatinase: A activity in buccal mucosal fibroblasts by arecoline as possible mechanisms for oral submucous fibrosis. Oral Oncol. 2002, 38 (2): 195-200. 10.1016/S1368-8375(01)00045-8.CrossRefPubMed

38.

Nishizawa R, Nagata M, Noman AA, Kitamura N, Fujita H, Hoshina H, Kubota T, Itagaki M, Shingaki S, Ohnishi M, Kurita H, Katsura K, Saito C, Yoshie H, Takagi R: The 2G allele of promoter region of matrix metalloproteinase-1 as an essential pre-condition for the early onset of oral squamous cell carcinoma. BMC Cancer. 2007, 7: 187-10.1186/1471-2407-7-187.CrossRefPubMedPubMedCentral

39.

McCawley L, Crawford H, King L, Mudgett J, Matrisian L: Aprotective role for matrix metalloproteinase-3 in squamous cell carcinoma. Cancer Res. 2004, 64: 6965-6972. 10.1158/0008-5472.CAN-04-0910.CrossRefPubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/10/369/prepub

Title: Synergistic effect of stromelysin-1 (matrix metalloproteinase-3) promoter (-1171 5A->6A) polymorphism in oral submucous fibrosis and head and neck lesions
Authors: Ajay K Chaudhary
Mamta Singh
Alok C Bharti
Mangal Singh
Shirish Shukla
Atul K Singh
Ravi Mehrotra
Publication date: 01-12-2010
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/1471-2407-10-369

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2010

An experimental study on cervix cancer with combination of HSV-TK/GCV suicide gene therapy system and 60Co radiotherapy

Ras-association domain family 1C protein promotes breast cancer cell migration and attenuates apoptosis

TrkB is highly expressed in NSCLC and mediates BDNF-induced the activation of Pyk2 signaling and the invasion of A549 cells

Internal mammary lymph node recurrence: rare but characteristic metastasis site in breast cancer

The apoptotic response in HCT116 BAX-/- cancer cells becomes rapidly saturated with increasing expression of a GFP-BAX fusion protein

Signal transduction mechanisms involved in S100A4-induced activation of the transcription factor NF-κB

Keynote webinar | Spotlight on antibody–drug conjugates in cancer